Healthcare >> Analyst Interviews >> December 18, 2000
ROBERT TOTH, JR. is a Senior Analyst with the Prudential Vector
Healthcare Group, covering biotechnology companies focusing on cancer
therapeutics, genomic platforms, and neuroscience applications. He
joined Prudential Securities via the July 1999 acquisition of Vector
Securities International, Inc. Prior to joining Vector, Mr. Toth served
as Business Development Analyst with the biotechnology company
Connectics Corp. He received his BBA in Biology and Biochemistry from
California State Polytechnic University, and an MBA from the University
of Washington School of Business. Profile
PETER F. DRAKE, PhD is a Managing Director of Equity Research with
Prudential Vector Healthcare Group, where he also serves as co-Founder
and Executive Vice President of Vector Securities International.
Previously, he served as a Senior Research Analyst covering
biotechnology and biomedical products with Kidder, Peabody. Dr. Drake
holds a Doctoral degree in Neurobiology and Biochemistry from Bryn Mawr
College and a CBA from the Wharton School of Business at the University
of Pennsylvania. Profile
CHARLES C. DUNCAN, PhD, CFA, is a Senior Biotechnology Analyst at
Prudential Vector Healthcare Group, covering genomics companies. He was
previously associated with Tucker Anthony Cleary Gull, Inc. where he was
Senior Vice President covering biotech and emerging pharmaceutical
companies. Dr. Duncan has passed Level I of the Chartered Financial
Analyst (CFA) program and he received a BS in Zoology from the
University of Wisconsin-Madison. and a PhD from the University of
Colorado in Pharmaceutical Sciences. JOHN S. SONNIER is a Senior
Biotechnology Analyst with the Prudential Vector Healthcare Group,
focusing on small, mid- and large cap companies in the areas of
infectious disease, transfusion medicine and neuroscience. He joined
Prudential Securities via the July 1999 acquisition of Vector Securities
International, Inc. Prior to joining Vector, Mr. Sonnier spent eight
years in the pharmaceutical industry at Johnson & Johnson and Baxter
and, most recently, as the Senior Healthcare Planning Manager at Baxter
Healthcare Corporation, Biotech Group. He received his BS degree in
Business from the University of Southern Mississippi. Profile
approach that the Prudential Vector Healthcare Group takes to investing
in biotechnology?
Dr. Drake: I think it's a combination
